{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:06:18Z","timestamp":1773889578633,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.biopha.2012.10.017","type":"journal-article","created":{"date-parts":[[2012,11,19]],"date-time":"2012-11-19T16:15:37Z","timestamp":1353341737000},"page":"157-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dihydroartemisinin inhibits the Bcr\/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib"],"prefix":"10.1016","volume":"67","author":[{"given":"Jun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiqiang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.10.017_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.biopha.2012.10.017_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.10.017_bib0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm0804-786","article-title":"Treating cancer's kinase \u201caddiction\u201d","volume":"10","author":"Baselga","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.biopha.2012.10.017_bib0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.10.017_bib0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biopha.2012.10.017_bib0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2012.10.017_bib0035","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopha.2012.10.017_bib0040","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.23435","article-title":"Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl\/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification","volume":"122","author":"Morinaga","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biopha.2012.10.017_bib0045","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopha.2012.10.017_bib0050","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","article-title":"A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.017_bib0055","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"Shi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.017_bib0060","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.leukres.2010.11.012","article-title":"A small molecule significantly inhibits the bcr\/abl fusion gene at the mRNA level in human chronic myelogenous leukemia","volume":"35","author":"He","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.biopha.2012.10.017_bib0065","doi-asserted-by":"crossref","first-page":"247597","DOI":"10.1155\/2012\/247597","article-title":"Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug","volume":"2012","author":"Crespo-Ortiz","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.biopha.2012.10.017_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-005-0002-y","article-title":"Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells","volume":"57","author":"Lee","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.biopha.2012.10.017_bib0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.vph.2007.05.002","article-title":"Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells","volume":"47","author":"Zhou","year":"2007","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.biopha.2012.10.017_bib0080","first-page":"89","article-title":"Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia","volume":"1","author":"Ebos","year":"2002","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2012.10.017_bib0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.0960-135X.2004.01365.x","article-title":"Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr\/abl oncogene, biochemical mechanisms, and potential clinical implications","volume":"34","author":"Sillaber","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.biopha.2012.10.017_bib0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10245330701384179","article-title":"Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells","volume":"12","author":"Baran","year":"2007","journal-title":"Hematology"},{"key":"10.1016\/j.biopha.2012.10.017_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10495-011-0580-6","article-title":"Interruption of the MEK\/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo","volume":"16","author":"Gao","year":"2011","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2012.10.017_bib0100","first-page":"13","article-title":"New strategies in controlling drug resistance","volume":"13","author":"Frame","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.biopha.2012.10.017_bib0105","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.017_bib0110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.10.017_bib0115","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.017_bib0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1745-7254.2006.00282.x","article-title":"Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials","volume":"27","author":"Thomas","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.biopha.2012.10.017_bib0125","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.biopha.2012.10.017_bib0130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia \u2013 signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.biopha.2012.10.017_bib0135","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","article-title":"Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3","volume":"91","author":"Amarante-Mendes","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.10.017_bib0140","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood.V91.7.2415","article-title":"BCR-ABL delays apoptosis upstream of procaspase-3 activation","volume":"91","author":"Dubrez","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2012.10.017_bib0145","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/107327480901600202","article-title":"Signaling networks associated with BCR-ABL-dependent transformation","volume":"16","author":"Hazlehurst","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.biopha.2012.10.017_bib0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-009-1218-7","article-title":"The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alpha in human rheumatoid arthritis fibroblast-like synoviocyte","volume":"31","author":"He","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.biopha.2012.10.017_bib0155","doi-asserted-by":"crossref","first-page":"046028","DOI":"10.1117\/1.3481141","article-title":"Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques","volume":"15","author":"Lu","year":"2010","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.biopha.2012.10.017_bib0160","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.canlet.2008.09.023","article-title":"Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis","volume":"274","author":"Nakase","year":"2009","journal-title":"Cancer Lett"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:51:14Z","timestamp":1760093474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0753332212001096"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.017","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydroartemisinin inhibits the Bcr\/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}